PTH and chronic kidney disease: The major treatment for SHPT in CKD patients is calcimimetics, together with active vitamin D. In experimental studies, both calcimimetics – R568 and AMG641 – were shown to reduce high-serum PTH in uremic rats with SHPT without increasing serum calcium or phosphate, in contrast to active vitamin D sterols, thereby preventing the development of extraskeletal calcification (34).